Ionis Pharmaceuticals, Inc.
IONS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.61 | -0.57 | -0.02 | 1.60 |
| FCF Yield | -10.45% | -4.64% | -5.50% | 0.30% |
| EV / EBITDA | -18.10 | -35.14 | -28.32 | -900.76 |
| Quality | ||||
| ROIC | -17.34% | -14.95% | -19.23% | -1.25% |
| Gross Margin | 98.41% | 98.84% | 97.60% | 98.66% |
| Cash Conversion Ratio | 1.10 | 0.84 | 1.02 | -1.08 |
| Growth | ||||
| Revenue 3-Year CAGR | 6.28% | -0.95% | -6.96% | -10.29% |
| Free Cash Flow Growth | -62.80% | -13.94% | -2,383.06% | 350.16% |
| Safety | ||||
| Net Debt / EBITDA | -3.32 | -4.47 | -4.80 | -73.60 |
| Interest Coverage | -5.25 | -4.34 | -50.50 | -3.23 |
| Efficiency | ||||
| Inventory Turnover | 0.90 | 1.23 | 0.64 | 0.44 |
| Cash Conversion Cycle | -943.36 | -697.48 | 122.19 | 462.23 |